NCT06265545
- Conditions
- AML, Disease Attributes, Pathologic Processes, +4 more
- Locations
-
- Blood Hospital Tianjin, China
Clinical trial condition
Relapsed
Explore clinical trials studying Relapsed. Study availability and eligibility vary by location and protocol.
5 public trials
3 recruiting studies
Relapsed trial results
NCT02677064
- Conditions
- Acute Leukemia, Disease Attributes, Newly Diagnosed, +4 more
- Locations
-
- Hartford Healthcare Cancer Institute @ Hartford Hospital Hartford, Connecticut, United States
- Memorial Sloan Kettering Cancer Center New York, United States
- Lehigh Valley Health Network Allentown, Pennsylvania, United States
Recruiting
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
NCT06732232
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +18 more
- Locations
-
- China, Shanghai Mengchao Cancer Hospital Shanghai, China
Active, not recruiting
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
NCT03179930
- Conditions
- Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
- Locations
-
- Northwestern University (Data Collection Only) Evanston, Illinois, United States
- Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
Active, not recruiting
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
NCT03085173
- Conditions
- Chronic Disease, Chronic Lymphocytic Leukemia (CLL), Disease Attributes, +17 more
- Locations
-
- Memorial Sloan Kettering Cancer Center New York, United States